Health Condition 1: O092- Supervision of pregnancy with other poor reproductive or obstetric history Health Condition 2: O092- Supervision of pregnancy with other poor reproductive or obstetric history Health Condition 3: O092- Supervision of pregnancy with other poor reproductive or obstetric history
Conditions
Interventions
Intervention1: Group 1 (IVIG group): Patients randomised in group 1 (IVIG group) will receive IVIG along with routine care. The active drug used was 5% formulation of intact type human immunoglobulin
Sponsors
All india Institute of Medical Sciences, New delhi
Eligibility
Inclusion criteria
Inclusion criteria: 1) Age 18-40 years 2) Pregnant women with 3 or more unexplained pregnancy losses 3) Primary or secondary RPL
Exclusion criteria
Exclusion criteria: 1) Previous biochemical pregnancy loss will not be included 2) Fetus with congenital anomaly 3) Any uterine anomaly 4) Autoimmune disorder 5) Thyroid dysfunction 6) APLA 7) Thrombophilia 8) Insulin dependent DM 9) IVF pregnancy 10) Total IgA deficiency 11) Parental chromosomal abnormality 12) Not willing to participate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome will be the ongoing pregnancy rate at 22 weeks of gestation. Secondary outcome will be to compare live birth rate in both the groups and risk of fetal growth restriction (FGR) and preterm delivery (PTB) in intervention groupTimepoint: Till delivery | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome will be to compare live birth rate in both the groups and risk of fetal growth restriction (FGR) and preterm delivery (PTB) in intervention groupTimepoint: Till delivery | — |
Countries
India
Contacts
Public ContactDr Neha Varun
All India Institute of medical sciences, New Delhi
Outcome results
None listed